Kaufmann G R, Cooper D A
National Centre in HIV Epidemiology and Clinical Research, Level 2, 376 Victoria Street, NSW 2010, Sydney, Australia.
Curr Opin Microbiol. 2000 Oct;3(5):508-14. doi: 10.1016/s1369-5274(00)00131-4.
Recently, studies have shown that non-nucleoside reverse transcriptase inhibitors, such as efavirenz or nevirapine, in combination with two nucleoside analogues have an antiretroviral potency comparable to protease inhibitor containing regimens. Triple combination therapy that includes a non-nucleoside reverse transcriptase inhibitor can therefore be regarded as an effective alternative first-line treatment of HIV-1 infection.